Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206500 · ClinicalTrials.gov registry record · Phase 4
NextGen - Clinical Implication of Next Generation Sequencing
A Phase 4 study of Urinary Tract Infections, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05206500: Recruiting Phase 4 study of Urinary Tract Infections, sponsored by Wake Forest University Health Sciences.
NCT05206500 is a Phase 4 study of Urinary Tract Infections that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants, below the 455-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05206500, a Phase 4 study of Urinary Tract Infections, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Recently more advanced techniques, including Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) are available to detect bacteria in urine based on bacterial genomes. Comparing to traditional culture, these techniques have more sensitivity and could potentially be of a great help in patients with Colony Count of less than 10,000 and more than zero.
Primary Outcome
NGS Ability to Detect Bacteria among patients with UTI Colony Count (CC) of Bacteria \<10,000. Result Measure: NGS CC 100 to 10,000
Conditions Studied
Interventions
- DRUG Antibiotic
- DEVICE Next Gen
Study Locations (1)
North Carolina
- Wake Forest Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
What NCT05206500 shows while recruiting
NCT05206500 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 455-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Urinary Tract Infections appearing as the primary indexed condition, and to 2 interventions - of which Antibiotic is the first listed.
NCT05206500 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05206500 about?
NCT05206500 is a clinical study titled "NextGen - Clinical Implication of Next Generation Sequencing". Recently more advanced techniques, including Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) are available to detect bacteria in urine based on bacterial genomes. Comparing to traditional culture, these techniques have more sensitivity and could potentially be of a great help in...
What is the current status of trial NCT05206500?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2022-05-17. Estimated completion is 2028-12.
What conditions does trial NCT05206500 study?
This clinical trial studies the following conditions: Urinary Tract Infections.
What interventions are being tested in trial NCT05206500?
The interventions under investigation include: Antibiotic (DRUG), Next Gen (DEVICE).
Who is sponsoring clinical trial NCT05206500?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206500 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05206500's enrollment target sits among peer trials
100 23rd of 34 higher than 11 of 34 other Urinary Tract Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Tract Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chlorhexidine Lavage for Recurrent Urinary Tract Infection
ACTIVE NOT RECRUITING · Phase 4
-
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
RECRUITING · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
RECRUITING
-
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI